Is there association between statin usage and contrast-associated acute kidney injury after intravenous administration of iodine-based contrast media in enhanced computed tomography?

• Published in: European radiology 2020-10, Vol.30 (10), p.5261-5271
• Main Authors: Park, Jae Hyon, Shin, Hye Jung, Choi, Jin-Young, Lim, Joon Seok, Park, Mi-Suk, Kim, Myeong-Jin, Oh, Hyung Jung, Chung, Yong Eun
• Format: Article
• Language: English
• Subjects: Acute Kidney Injury - chemically induced; Acute Kidney Injury - drug therapy; Administration, Intravenous; Aged; Computed tomography; Contrast agents; Contrast Media; Contrast Media - adverse effects; Diagnostic Radiology; Epidermal growth factor receptors; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Imaging; Internal Medicine; Interventional Radiology; Intravenous administration; Iodine; Iodine - adverse effects; Kidneys; Male; Medicine; Medicine & Public Health; Middle Aged; Neuroradiology; Radiology; Renal failure; Renal Insufficiency - etiology; Renal Insufficiency - prevention & control; Retrospective Studies; Statins; Subgroups; Tomography, X-Ray Computed - adverse effects; Ultrasound
• ISSN: 0938-7994; 1432-1084
• DOI: 10.1007/s00330-020-06897-4

Objectives Contrast-induced acute kidney injury (CI-AKI) is one of the leading causes of new-onset renal failure in hospitalized patients. Statin has been evaluated for its protective effect against CI-AKI but rarely in patients receiving intravenous (IV) administrations of iodine-based contrast media for enhanced computed tomography (CT). Methods In total, 12,371 patients who underwent contrast-enhanced abdominopelvic CT were retrospectively reviewed and stratified into statin users and statin nonusers. Subgroup analyses comparing high-intensity statins with low- to moderate-intensity statins were conducted within statin users and similar comparisons were performed within statin users stratified based on baseline eGFR. Results Overall, CI-AKI events did not occur less in statin users compared with non-statin users ( p  = 0.342). Within statin users, CI-AKI events did not decrease in high-intensity statin users compared with low- to moderate-intensity statin users ( p  = 0.355). Moreover, no significant difference in CI-AKI events was found between high-intensity statin users and low- to moderate-intensity statin users even after stratifying the patients with baseline eGFR. Conclusions Collectively, statin was not significantly associated with the risk of CI-AKI events in patients undergoing contrast-enhanced abdominopelvic CT and high-intensity statins did not show significant association with CI-AKI over low- to moderate-intensity statins in the subgroup analysis. Key Points • Statin is not associated with risk of CI-AKI events in patients undergoing intravenous administration of contrast-enhanced CT. • CI-AKI incidence among high-intensity statin users was not significantly different from that of low- to moderate-intensity statin users.